SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: Haim R. Branisteanu who wrote (87672)3/3/2012 12:51:43 PM
From: Cogito Ergo Sum  Respond to of 219525
 


Now I have a Waldorf salad to prepare :O)



To: Haim R. Branisteanu who wrote (87672)3/3/2012 9:19:02 PM
From: TobagoJack1 Recommendation  Read Replies (2) | Respond to of 219525
 
hello haim, a short and cogent message

From: R
Sent: Sunday, March 4, 2012 8:02 AM
Subject: Re: Comments - Week of March 5 - enveloping tyranny and rapid on-rush devolution

Looks like in addition to bottled water, dehydrated food, gas, gold, now I need to start stock piling drugs.

The European Federation of Pharmaceutical Industries and Associations noted that European states now owe 12 billion to 15 billion euros to companies such as Roche and Novartis. As of Dec. 31, 2011, the group's combined trade accounts (receivables) from the PIIGS came to 2.1 billion euros (not including zero-coupon bonds issued by Greece in lieu of payments owed.)

Faramindustria, the Spanish pharmaceutical industry association, said the Spanish health system owed various vendors $6.3 billion euros as of year-end 2011, up 36% from 2010. Late bills were being paid after an average of 525 days, stretching to 800 days late in certain autonomous regions.

Roche quietly reduced its shipments of certain medicines to Greek hospitals in 2011.

Novartis is debating whether to change its policies regarding countries with huge unpaid bills. A company spokesperson said, "Deteriorating credit and economic conditions ... have resulted in and may continue to result in requiring us to re-evaluate the collectability of these receivables in future periods.

"Pharma companies are private. In a liberal, democratic society, respect for private property is a fundamental value. A firm must maintain a good image for its customers and for the public to ensure it has a marketplace when the crisis is over. It's therefore in its interest to put in place ad hoc strategies like reducing drug prices temporarily.

"But the real problem will be if the crisis drags on. Without profit there is no innovation, and without that -- no future."

It would appear that most multinational drug companies are sitting on very large, unreserved bad receivables that will need to be converted to actual write-offs in the near future. This could be a significant reason that many of the shares of these same companies have languished for more than a decade, even as their reported earnings have surged.